Table 2.
Modified Fisher test of hsa-miR-148a-3p and clinical parameters.
| Characteristic | Low expression of hsa-miR-148a-3p | High expression of hsa-miR-148a-3p | P |
|---|---|---|---|
| n | 264 | 265 | |
| WHO grade, n (%) | 0.629 | ||
| G2 | 111 (23.8%) | 110 (23.6%) | |
| G3 | 117 (25.1%) | 129 (27.6%) | |
| IDH status, n (%) | <0.001 | ||
| WT | 5 (1%) | 92 (17.5%) | |
| Mut | 257 (48.9%) | 172 (32.7%) | |
| 1p/19q codeletion, n (%) | <0.001 | ||
| Codel | 114 (21.6%) | 58 (11%) | |
| Noncodel | 150 (28.4%) | 207 (39.1%) | |
| Primary therapy outcome, n (%) | 0.012 | ||
| PD | 42 (9.2%) | 68 (14.8%) | |
| SD | 80 (17.4%) | 68 (14.8%) | |
| PR | 37 (8.1%) | 26 (5.7%) | |
| CR | 78 (17%) | 60 (13.1%) | |
| Gender, n (%) | 0.405 | ||
| Female | 115 (21.7%) | 126 (23.8%) | |
| Male | 149 (28.2%) | 139 (26.3%) | |
| Race, n (%) | 0.369 | ||
| Asian | 6 (1.2%) | 2 (0.4%) | |
| Black or African American | 10 (1.9%) | 12 (2.3%) | |
| White | 242 (46.7%) | 246 (47.5%) | |
| Age, n (%) | 0.828 | ||
| ≤40 | 130 (24.6%) | 134 (25.3%) | |
| >40 | 134 (25.3%) | 131 (24.8%) | |
| Histological type, n (%) | 0.014 | ||
| Astrocytoma | 83 (15.7%) | 113 (21.4%) | |
| Oligoastrocytoma | 67 (12.7%) | 66 (12.5%) | |
| Oligodendroglioma | 114 (21.6%) | 86 (16.3%) | |
| Laterality, n (%) | 0.392 | ||
| Left | 135 (25.8%) | 122 (23.3%) | |
| Midline | 3 (0.6%) | 4 (0.8%) | |
| Right | 122 (23.3%) | 138 (26.3%) | |
| OS event, n (%) | <0.001 | ||
| Alive | 217 (41%) | 177 (33.5%) | |
| Dead | 47 (8.9%) | 88 (16.6%) | |
| DSS event, n (%) | <0.001 | ||
| Alive | 220 (42.2%) | 179 (34.4%) | |
| Dead | 41 (7.9%) | 81 (15.5%) | |
| PFI event, n (%) | 0.003 | ||
| Alive | 177 (33.5%) | 143 (27%) | |
| Dead | 87 (16.4%) | 122 (23.1%) |
Annotation: DSS: disease-specific survival; PFI: disease-free interval.